Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III long-term open-label study of AFT-801 (modafinil) for excessive daytime sleepiness in CPAP-treated obstructive sleep apnea
jRCT2080220353Phase 3
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of modafinil in obstructive sleep apnea hypopnea syndrome (OSAHS) and Excessive Daytime Sleepiness (EDS), sponsored by Mitsubishi Tanabe Pharma Corporation.
02
Drugs
modafinil
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on jRCT2080220353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220353.